Aerie Pharmaceuticals announced the submission of its New Drug Application (NDA) to the FDA for Rhopressa (netarsudil ophthalmic solution) 0.02%....
Aerie Pharmaceuticals, Inc. reported the successful results of its second Phase III trial for Rhopressa, a novel once-daily, triple-action eye...
Aerie Pharmaceuticals has reported the results of its first Phase III registration trial (Rocket 1) for Rhopressa, a novel once-daily,...
Aerie Pharmaceuticals, Inc. reported the successful 90-day topline efficacy results of its Rocket 4 Phase III clinical trial of product...
Aerie Pharmaceuticals, Inc.has announced topline efficacy results from a double-masked, randomized, placebo-controlled study (AR-13324-CS206; NCT03233308) designed to evaluate the effect...
Aerie Pharmaceuticals, Inc. announced that, in their review of Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, the members of...
Aerie Pharmaceuticals, Inc. reported the successful primary efficacy results of the Company's 90-day Phase III Mercury 2" registration trial for...
Aerie Pharmaceuticals announced that the FDA has approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure...